Insights into the Possible Molecular Mechanisms of Resistance to PARP Inhibitors

SIMPLE SUMMARY: The increasingly wide use of PARP inhibitors in breast, ovarian, pancreatic, and prostate cancers harbouring a pathogenic variant in BRCA1 or BRCA2 has highlighted the problem of resistance to therapy. This review summarises the complex interactions between PARP1, cell cycle regulati...

Descripción completa

Detalles Bibliográficos
Autores principales: Piombino, Claudia, Cortesi, Laura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9179506/
https://www.ncbi.nlm.nih.gov/pubmed/35681784
http://dx.doi.org/10.3390/cancers14112804

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9179506/
https://www.ncbi.nlm.nih.gov/pubmed/35681784
http://dx.doi.org/10.3390/cancers14112804

Ejemplares similares